

Anagrelide (hydrochloride)

Catalog No: tcsc2743



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

58579-51-4

Formula:

$C_{10}H_8Cl_3N_3O$

Pathway:

Metabolic Enzyme/Protease

Target:

Phosphodiesterase (PDE)

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

BL4162A

Observed Molecular Weight:


292.55

Product Description

Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.

Target: PDE

Anagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine [1]. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!